KYMERA THERAPEUTICS, INC. Finance Lease, Interest Payment on Liability
KYMERA THERAPEUTICS, INC. (KYMR) reported Finance Lease, Interest Payment on Liability of $861.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FinanceLeaseInterestPaymentOnLiability · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. finance lease, interest payment on liability for the quarter ending 2026-06-30 was $435.00K, a 31.82% increase year-over-year.
- KYMERA THERAPEUTICS, INC. finance lease, interest payment on liability for the quarter ending 2026-03-31 was $426.00K, a 42.47% increase year-over-year.
- KYMERA THERAPEUTICS, INC. finance lease, interest payment on liability for the quarter ending 2025-12-31 was $417.00K, a 22.29% increase year-over-year.
- KYMERA THERAPEUTICS, INC. finance lease, interest payment on liability for the quarter ending 2025-09-30 was $448.00K, a 63.50% increase year-over-year.
- KYMERA THERAPEUTICS, INC. finance lease, interest payment on liability for fiscal 2025 was $1.49M, a 10.58% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. finance lease, interest payment on liability for fiscal 2024 was $1.35M, a 0.88% decline from fiscal 2023.
- KYMERA THERAPEUTICS, INC. finance lease, interest payment on liability for fiscal 2023 was $1.36M, a 20.62% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. finance lease, interest payment on liability for fiscal 2022 was $1.13M, a 21.11% increase from fiscal 2021.
| Period end | Finance Lease, Interest Payment on Liability 3 month | Finance Lease, Interest Payment on Liability 6 month | Finance Lease, Interest Payment on Liability 9 month | Finance Lease, Interest Payment on Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $435.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $861.00K 10-Q · filed 2026-08-05 | $1.28M derived: sum of 3 quarters · filed 2026-08-05 | $1.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $426.00K 10-Q · filed 2026-04-30 | $843.00K derived: sum of 2 quarters · filed 2026-04-30 | $1.29M derived: sum of 3 quarters · filed 2026-04-30 | $1.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $417.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $865.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.20M derived: sum of 3 quarters · filed 2026-08-05 | $1.49M 10-K · filed 2026-02-26 |
| 2025-09-30 | $448.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $778.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.08M 10-Q · filed 2025-11-04 | $1.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $330.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $629.00K 10-Q · filed 2026-08-05 | $970.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $299.00K 10-Q · filed 2026-04-30 | $640.00K derived: sum of 2 quarters · filed 2026-04-30 | $914.00K derived: sum of 3 quarters · filed 2026-04-30 | $1.27M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $341.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $615.00K derived: sum of 2 quarters · filed 2026-02-26 | $968.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.35M 10-K · filed 2026-02-26 |
| 2024-09-30 | $274.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $627.00K derived: sum of 2 quarters · filed 2025-11-04 | $1.01M 10-Q · filed 2025-11-04 | $1.37M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $353.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $736.00K 10-Q · filed 2025-08-11 | $1.10M derived: sum of 3 quarters · filed 2025-08-11 | $1.44M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $383.00K 10-Q · filed 2025-05-09 | $745.00K derived: sum of 2 quarters · filed 2025-05-09 | $1.08M derived: sum of 3 quarters · filed 2025-05-09 | $1.42M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $362.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $702.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.04M derived: sum of 3 quarters · filed 2025-02-27 | $1.36M 10-K · filed 2025-02-27 |
| 2023-09-30 | $340.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $674.00K derived: sum of 2 quarters · filed 2024-10-31 | $1.00M 10-Q · filed 2024-10-31 | $1.30M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $334.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $661.00K 10-Q · filed 2024-08-07 | $958.00K derived: sum of 3 quarters · filed 2024-08-07 | $1.30M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $327.00K 10-Q · filed 2024-05-02 | $624.00K derived: sum of 2 quarters · filed 2024-05-02 | $968.00K derived: sum of 3 quarters · filed 2024-05-02 | $1.19M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $641.00K derived: sum of 2 quarters · filed 2024-02-22 | $866.00K derived: sum of 3 quarters · filed 2024-02-22 | $1.13M 10-K · filed 2024-02-22 |
| 2022-09-30 | $344.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $569.00K derived: sum of 2 quarters · filed 2023-11-02 | $833.00K 10-Q · filed 2023-11-02 | $1.17M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $225.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $489.00K 10-Q · filed 2023-08-03 | $829.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.07M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $264.00K 10-Q · filed 2023-05-04 | $604.00K derived: sum of 2 quarters · filed 2023-05-04 | $847.00K derived: sum of 3 quarters · filed 2023-05-04 | $1.04M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $583.00K derived: sum of 2 quarters · filed 2023-02-23 | $778.00K derived: sum of 3 quarters · filed 2023-02-23 | $933.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $243.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $438.00K derived: sum of 2 quarters · filed 2022-11-03 | $593.00K 10-Q · filed 2022-11-03 | $743.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $195.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $350.00K 10-Q · filed 2022-08-09 | $500.00K derived: sum of 3 quarters · filed 2022-08-09 | $628.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $155.00K 10-Q · filed 2022-05-03 | $305.00K derived: sum of 2 quarters · filed 2022-05-03 | $433.00K derived: sum of 3 quarters · filed 2022-05-03 | $600.00K derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | $150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $278.00K derived: sum of 2 quarters · filed 2022-02-24 | $445.00K derived: sum of 3 quarters · filed 2022-02-24 | $587.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $128.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $295.00K derived: sum of 2 quarters · filed 2021-11-10 | $437.00K 10-Q · filed 2021-11-10 | $230.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $167.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $309.00K 10-Q · filed 2021-08-06 | $102.00K derived: sum of 3 quarters · filed 2021-08-06 | |
| 2020-03-31 | $142.00K 10-Q · filed 2021-05-06 | -$65.00K derived: sum of 2 quarters · filed 2021-05-06 | ||
| 2019-12-31 | -$207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $46.00K 10-K · filed 2021-03-11 | ||
| 2019-09-30 | $253.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |